Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Endoxifen (Primary)
- Indications Breast cancer; Endometrial cancer; Fallopian tube cancer; Fibroma; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Adverse reactions
- 25 Feb 2017 Planned End Date changed from 31 Oct 2017 to 31 Oct 2018.
- 25 Feb 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Oct 2018.
- 02 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.